RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study will be divided into 2 parts. Part 1 is a randomized, double-blind, single centre,
placebo-controlled, single ascending dose (SAD) phase I study designed to assess the safety,
tolerability, PK and PD (Pharmacodynamic) of TD139 in up to 36 healthy male subjects. Part 2
will be a randomized, double-blind, multi-centre, placebo-controlled, multiple dose expansion
cohort, designed to assess the safety, tolerability, PK and PD of TD139 in up to 24 male
subjects and female subjects of non child-bearing potential with IPF.